EQUITY ALERT: ROSEN, A LEADING AND RANKED LAW FIRM, Announces Investigation of Securities Claims Against Applied Therapeutics, Inc. – APLT

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) resulting from allegations that Applied Therapeutics may have issued materially misleading business information to the investing public.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, August 19, 2020
Information
Tags: 
Legal, Professional services, Stock market, Stock, Security, Securities Class Action, Economy, Academic disciplines, Robbins Geller Rudman & Dowd LLP
Geotags: 
United States, NEW YORK
Summary
Key Points: 
  • Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) resulting from allegations that Applied Therapeutics may have issued materially misleading business information to the investing public.
  • On this news, Applied Therapeutics stock price fell $3.53 per share, or 12%, to close at $25.71 per share on August 17, 2020.
  • Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Applied Therapeutics investors.
  • Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.


Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) resulting from allegations that Applied Therapeutics may have issued materially misleading business information to the investing public.

On August 17, 2020, Applied Therapeutics disclosed that the U.S. Food and Drug Administration (“FDA”) has placed a partial clinical hold on the Company's ACTION-Kids study evaluating the Company's AT-007 product for the treatment of galactosemia. The FDA cited the need for additional technical information related to ensuring that every participant in the study has access to the drug's benefits.

On this news, Applied Therapeutics’ stock price fell $3.53 per share, or 12%, to close at $25.71 per share on August 17, 2020.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Applied Therapeutics’ investors. If you purchased shares of Applied Therapeutics, please visit the firm’s website at http://www.rosenlegal.com/cases-register-1928.html to join the class action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Copyright: 
Copyright Business Wire 2020